Phone:
+1 877 302 8632
Fax:
+1 888 205 9894 (Toll-free)
E-Mail:
orders@antibodies-online.com

HLA-DRA antibody

HLA-DRA Reactivity: Human, Mouse, Rat WB, IHC, IF, ELISA, ICC Host: Rabbit Polyclonal unconjugated
Catalog No. ABIN6262290
  • Target See all HLA-DRA Antibodies
    HLA-DRA (HLA Class II DR alpha (HLA-DRA))
    Reactivity
    • 85
    • 17
    • 10
    • 9
    • 9
    • 8
    • 3
    • 2
    • 2
    • 1
    Human, Mouse, Rat
    Host
    • 56
    • 43
    • 2
    • 1
    Rabbit
    Clonality
    • 58
    • 44
    Polyclonal
    Conjugate
    • 49
    • 12
    • 5
    • 3
    • 3
    • 3
    • 3
    • 3
    • 3
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 2
    • 1
    • 1
    This HLA-DRA antibody is un-conjugated
    Application
    • 46
    • 43
    • 33
    • 29
    • 15
    • 10
    • 10
    • 9
    • 9
    • 3
    • 3
    • 3
    • 1
    • 1
    • 1
    Western Blotting (WB), Immunohistochemistry (IHC), Immunofluorescence (IF), ELISA, Immunocytochemistry (ICC)
    Specificity
    HLA-DRA Antibody detects endogenous levels of total HLA-DRA
    Cross-Reactivity
    Human, Mouse (Murine), Rat (Rattus)
    Purification
    The antiserum was purified by peptide affinity chromatography using SulfoLinkTM Coupling Resin (Thermo Fisher Scientific).
    Immunogen
    A synthesized peptide derived from human HLA-DRA
    Isotype
    IgG
    Top Product
    Discover our top product HLA-DRA Primary Antibody
  • Application Notes
    WB 1:500-1:2000 IHC 1:50-1:200, IF/ICC 1:100-1:500
    Restrictions
    For Research Use only
  • Format
    Liquid
    Concentration
    1 mg/mL
    Buffer
    Rabbit IgG in phosphate buffered saline ,  pH 7.4, 150  mM NaCl, 0.02 % sodium azide and 50 % glycerol.
    Preservative
    Sodium azide
    Precaution of Use
    This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
    Storage
    -20 °C
    Storage Comment
    Store at -20 °C.Stable for 12 months from date of receipt
    Expiry Date
    12 months
  • Target
    HLA-DRA (HLA Class II DR alpha (HLA-DRA))
    Alternative Name
    HLA-DRA (HLA-DRA Products)
    Synonyms
    HLA-DRA1 antibody, MLRW antibody, DR-alpha antibody, HLA-DRA antibody, Mamu-DRA1 antibody, major histocompatibility complex, class II, DR alpha L homeolog antibody, major histocompatibility complex, class II, DR alpha antibody, hla-dra.L antibody, HLA-DRA antibody, MAMU-DRA antibody, BOLA-DRA antibody
    Background

    Description: Binds peptides derived from antigens that access the endocytic route of antigen presenting cells (APC) and presents them on the cell surface for recognition by the CD4 T-cells. The peptide binding cleft accommodates peptides of 10-30 residues. The peptides presented by MHC class II molecules are generated mostly by degradation of proteins that access the endocytic route, where they are processed by lysosomal proteases and other hydrolases. Exogenous antigens that have been endocytosed by the APC are thus readily available for presentation via MHC II molecules, and for this reason this antigen presentation pathway is usually referred to as exogenous. As membrane proteins on their way to degradation in lysosomes as part of their normal turn-over are also contained in the endosomal/lysosomal compartments, exogenous antigens must compete with those derived from endogenous components. Autophagy is also a source of endogenous peptides, autophagosomes constitutively fuse with MHC class II loading compartments. In addition to APCs, other cells of the gastrointestinal tract, such as epithelial cells, express MHC class II molecules and CD74 and act as APCs, which is an unusual trait of the GI tract. To produce a MHC class II molecule that presents an antigen, three MHC class II molecules (heterodimers of an alpha and a beta chain) associate with a CD74 trimer in the ER to form a heterononamer. Soon after the entry of this complex into the endosomal/lysosomal system where antigen processing occurs, CD74 undergoes a sequential degradation by various proteases, including CTSS and CTSL, leaving a small fragment termed CLIP (class-II-associated invariant chain peptide). The removal of CLIP is facilitated by HLA-DM via direct binding to the alpha-beta-CLIP complex so that CLIP is released. HLA-DM stabilizes MHC class II molecules until primary high affinity antigenic peptides are bound. The MHC II molecule bound to a peptide is then transported to the cell membrane surface. In B-cells, the interaction between HLA-DM and MHC class II molecules is regulated by HLA-DO. Primary dendritic cells (DCs) also to express HLA-DO. Lysosomal microenvironment has been implicated in the regulation of antigen loading into MHC II molecules, increased acidification produces increased proteolysis and efficient peptide loading.

    Gene: HLA-DRA

    Molecular Weight
    29kDa
    Gene ID
    3122
    UniProt
    P01903
    Pathways
    TCR Signaling, CXCR4-mediated Signaling Events, Human Leukocyte Antigen (HLA) in Adaptive Immune Response
You are here:
Support